Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2029

Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
RADIATION

Cisplatin-based Radiation Therapy

"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."

DRUG

Cisplatin Chemotherapy

"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."

Trial Locations (4)

90048

Cedars-Sinai Medical Center (Beverly - Main Site), Los Angeles

90211

Tower Hematology-Oncology, Beverly Hills

90505

Torrance Memorial Physician Network Cancer Care, Torrance

91356

Valley Oncology Medical Group, Tarzana

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER